Skip to main content
Equibles
DNTH logo

DNTH · Dianthus Therapeutics, Inc.

Track DNTH — free

Use DNTH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DNTH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$91.81 -0.67 (-0.72%) At close · Nov 13
Russell 2000 member Rebalance outlook locked
Market Cap
$5.17B
Shares
56.31M
Volume · Nov 13 681.54K Avg daily vol (3M) 846.68K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$91.81 Open$91.87 Day$88.61–92.34 52W close$35.50–115.96 Avg vol 30d934K Short int9.3M · 16.5% of shares · 10.1d Short vol66% Last earningsMar 9, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Q4 2025 earnings call transcript
call held Mar 9, 2026
Play latest call

Latest documents

2026
Nov 11
Investor event
Cash runway reaches 2030 as key trials advance

Dianthus Therapeutics expects $1.2 billion cash to fund operations into 2030, with clasipibart Phase II MMN data expected in December and full CIDP Part A data by end of next year.

3 source passages
Yeah, we have $1.2 billion cash. We're very fortunate. That takes us into 2030 and allows us to read pretty much every major catalyst between now and then and start to build out the commercial organization for launching Klasipibart. Speaking of MMN, we are expecting data from our Phase II in December. we're guided to full Part A data at the end of next year Open the document at this passage
Nov 9
Investor event
Claspirobar shows 75% CIDP response; cash funds operations into 2030

Dianthus says Claspirobar produced 75% responses in the first 40 Part A patients, Part B is ahead of schedule, MMN Phase 2 results are expected in December, and $1.2 billion funds operations into 2030.

7 source passages
So just quickly on Claspirobar, I'll just focus on our lead program, our active, very potent active C1S inhibitor. We are seeing 75% responder rates in our first 40 patient interim responder analysis. That's why we're seeing better efficacy. I think in CIDP, it matters. Potency matters. So despite that, we're moving our timelines ahead. And that's because of the amazing team we have that's, you know, we're in over 200 sites and they're doing a great job of making sure that we're recruiting enough patients. And because of the elevated efficacy responder rates we're seeing in part A. So our part B is ahead of schedule. focusing on Momentum or our MMN Phase 2 trial that's coming up in December We have over-enrolled, we were targeting 12 patients. It's going to be about 15 patients per arm. We're over-enrolled, and we have 46 patients who have completed the study, and we expect the results in December. Yeah, we're very fortunate. We have $1.2 billion, and that takes us into 2030 Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Claseprubart CIDP trial posts 75% response rate

Dianthus Therapeutics reported a 75% interim response rate for claseprubart in the Phase 3 CAPTIVATE CIDP trial, exceeding its 50% or greater target. For the three months ended September 30, 2026, research and development expense was $45.6 million.

Net loss $46.64M Diluted EPS -$0.81
Read from the MD&A section
2 source passages
In June 2026, we announced a 75% response rate observed in the Interim Responder Analysis from the first 40 participants completing Part A of the Phase 3 CAPTIVATE trial, exceeding the target response rate of 50% or greater based on precedent set with aC1s inhibition. Research and development expenses were $45.6 million for the three months ended September 30, 2026, as compared to $32.5 million for the three months ended September 30, 2025, an increase of $13.1 million. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.04M
Trailing 12 months
Net income (TTM)
−$202.12M
Trailing 12 months
Revenue growth YoY
-78.6%
Year over year
Operating margin
-8,739.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$837.78M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+51.7%
Year over year · more shares
Price change (1Y)
+158.6%
Trailing year
Short interest
16.5%
Latest settlement · 10.1 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
· $874,000 −$13.75M '24 Q1 · $1.86M −$17.61M '24 Q2 ▲135.1% $2.17M −$25.17M '24 Q3 · $1.33M −$28.44M '24 Q4* ▲33.1% $1.16M −$29.51M '25 Q1 ▼89.6% $193,000 −$31.63M '25 Q2 ▼81.8% $396,000 −$36.77M '25 Q3 LATEST ▼78.6% $284,000 −$64.43M '25 Q4*

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +6%
above
Price vs 50-day avg +4%
above
RSI (14) 63
neutral
MACD trend Positive
52-week position 70%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +27%
trailing
6-month return +6%
trailing
YTD return +123%
this year
Relative strength +5%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $88 › 200d $87 — 50d above 200d
Institutional flow Accumulating
209 of 273 funds reported for Sep 30 · net +2.7M sh shares · +33 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.47% of shares out · ▲ +3.2% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
273 holders — near 3-yr high, broad support
Squeeze score 82
high risk · 0–100
Fundamentals
Weak
Revenue growth −67%
Y/Y
EPS growth −65%
Y/Y
Free cash flow $-129.4M
Balance sheet $51.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 60%
annualized · 1-yr
Max drawdown −38%
past year
ATR 4.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Feb 7, 2023
Severance and related costs · by the end of February 2023 $5.4M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+6% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
63 Neutral
MACD trend
Positive Bullish
52-week position
70% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $88 › 200d $87 — 50d above 200d
Institutional flow Accumulating
209 of 273 funds reported for Sep 30 · net +2.7M sh shares · +33 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.47% of shares out · ▲ +3.2% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
273 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $36 Now $92 · 70% Range high $116
vs 200-day avg +6% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Response rate (Interim Responder Analysis, Phase 3 CAPTIVATE Part A, CIDP) 75% Interim Responder Analysis —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DNTH
Dianthus Therapeutics, Inc.
this stock
$5.17B +122.8% -67.3% — 16.5%
VRTX
Vertex Pharmaceuticals Inc
 $136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
 $90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
289
% held
122.4%
Reported
209 of 273
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
325
View
Short & Settlement
Short Interest Rising
Shares short
9.3M
Days to cover
10.1d
Change
+289.9K sh
View
Short Volume
Short vol %
66%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
176
Value
$15.0K
As of
Oct 7, 2026
View
Off-Exchange
Off-exchange %
50.9%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.0M
Net income (FY)
$-162.3M
EPS diluted
$-4.20
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 11, 2026
This year
22

Dianthus Therapeutics expects $1.2 billion cash to fund operations into 2030, with clasipibart Phase II MMN data expected in December and full CIDP Part A data by end of next year.

View
Proposed Sales
Value
$10.7M
Shares
124.0K
Filed
Nov 9, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 16, 2026
Last webcast
Nov 11, 2026
View
Investor Relations
Latest news
DIANTHUS THERAPEUTICS HIGHLIGHTS…
Published
Nov 4, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
DNTH +6.7% +27.4% +5.8% +11.5% +122.8%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +4.1% +28.5% +5.3% +11.6% +112.2%
Key facts CIK 1690585 CUSIP 252828108 13F (30d) 195 filings 182 filers Visit website Investor relations